Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

July 9, 2018

Study Completion Date

July 31, 2018

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Daily injection of KBP/placebo for 12 weeks as add-on to metformin

Daily subcutaneous injection

Trial Locations (30)

2400

Bispebjerg Hospital, Endokrinologisk Afdeling, Bispebjerg

2750

Bioclinica, Ballerup Municipality

4300

Holbæk Sygehus, Holbæk

6700

Sydvestjysk Sygehus, Esbjerg

7100

Bioclinica, Vejle

8000

Aarhus University Hospital, Endocrinlogy Department, Aarhus

9000

Bioclinica, Aalborg

900412

S.C. Sfinx Medica S.R.L., Constanța

Unknown

Diabetologická a Obezitologická ambulance, České Budějovice

Diabet2 s.r.o, Prague

"Institutului Național de Diabet, Nutriție și Boli Metabolice Prof.Dr. N.C. Paulescu", Bucharest

S.C Nicodiab S.R.L., Bucharest

S.C. Mediab S.R.L., Târgu Mureş

360 17

Vdoviak Miroslav MUDr. - Interní Ambulance, Karlovy Vary

100 00

Interní a Diabetologická ambulance, Clintrial s.r.o, Prague

113 94

Endokrinologicky Ústav, Prague

128 00

General University Hospital, Prague

140 21

Institute for Clinical and experimental Medicine, Prague

68 601

Interní a Diabetologická ambulance, Uherské Hradiště

MD2025

Rtl Sm Srl/Scr, Chisinau

Rtl Sm Srl, Chisinau

80-546

Centrum Badań Klinicznych PI-House sp. z o.o., Gdansk

86-302

Specjalistyczna Praktyka Lekarska Piotr Kubalski, Grudziądz

31-261

Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczno, Krakow

90-074

Prywatny Gabinet Lekarski i Wizyty Lekarskie Jan Ruxer, Lodz

45-367

Prywatny Gabinet Lekarski M. Horodecki (budynek Medicus), Opole

43-100

Centrum Medyczne Hygea, Tychy

01-518

Centrum Medyczne AMED, Warsaw

030463

S.C. Policlinica CCBR S.R.L., Bucharest

WC1X 8QD

St. Pancras, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Nordic Bioscience A/S

INDUSTRY

lead

KeyBioscience AG

INDUSTRY

NCT03230786 - Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter